Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Rating of “Buy” from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have received a consensus rating of “Buy” from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $35.71.

Several research analysts have recently issued reports on DAWN shares. Needham & Company LLC restated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th.

Insider Activity at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $16.10, for a total value of $161,000.00. Following the sale, the insider now directly owns 1,057,535 shares of the company’s stock, valued at approximately $17,026,313.50. The trade was a 0.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 51,745 shares of company stock worth $748,567. 8.40% of the stock is owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after buying an additional 1,002 shares during the period. Quest Partners LLC boosted its position in Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after acquiring an additional 7,668 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth approximately $113,000. Point72 DIFC Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the second quarter valued at approximately $124,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Day One Biopharmaceuticals in the second quarter worth $163,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Down 0.2 %

Shares of DAWN stock opened at $12.87 on Monday. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -12.50 and a beta of -1.51. Day One Biopharmaceuticals has a 12 month low of $11.94 and a 12 month high of $18.07. The stock has a 50-day moving average price of $13.86 and a 200 day moving average price of $14.01.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same quarter in the prior year, the firm earned ($0.54) EPS. Sell-side analysts predict that Day One Biopharmaceuticals will post -0.88 earnings per share for the current fiscal year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.